News

Media

Conferences

Publications

Clinical

Events

Resources

Targeted Therapy Treatment Innovations in AML : Episode 2

Video

August 26, 2021

Role of Second Generation FLT3 Inhibitors in AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP, FHOPA

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.

EP: 1.Role of First Generation FLT3 Inhibitors in AML

EP: 2.Role of Second Generation FLT3 Inhibitors in AML

EP: 3.Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 4.Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 5.Role of Venetoclax in Treatment of AML

EP: 6.Part 1: Practical Considerations For Venetoclax in AML

EP: 7.Part 2: Practical Considerations For Venetoclax in AML

EP: 8.5-Year Follow-Up Data For CPX-351 in AML

EP: 9.CPX-351 in Clinical Practice For AML

Related Videos

Consent Preferences

Clinical Forums

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.